Agenus to Present AGEN1181 Clinical Data at SITC
October 01 2021 - 08:00AM
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an
extensive pipeline of checkpoint antibodies, cell therapies,
adjuvants, and vaccines designed to activate immune response to
cancers and infections, today announced acceptance of its abstract
describing updated Phase 1 clinical trial results for AGEN1181
(Fc-enhanced anti-CTLA-4) alone and in combination with balstilimab
(anti-PD-1) at the Society for Immunotherapy of Cancer (SITC) 36th
Annual Meeting, to be held November 10-14, 2021.
Presentation Details:
Abstract Title: AGEN1181, an
Fc-enhanced anti-CTLA-4 antibody, alone and in combination with
balstilimab (anti-PD-1) in patients with advanced solid tumors:
Initial phase I results (NCT03860272)Abstract
Number: 479Presenting Author: Dr. Anthony
El-Khoueiry
The full abstract will be released on Tuesday, November 9, 2021.
The updated data will be presented at the conference and will
become available in the investor section of our website at
https://investor.agenusbio.com/events-and-presentations following
the presentation on November 12, 2021.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics, adoptive cell
therapies (through its MiNK Therapeutics subsidiary), adjuvants,
and proprietary cancer vaccine platforms. The Company is equipped
with a suite of antibody discovery platforms and a state-of-the-art
GMP manufacturing facility with the capacity to support clinical
programs. Agenus is headquartered in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and Twitter.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements regarding potential therapeutic benefit and future
clinical development plans for balstilimab, zalifrelimab, and
AGEN1181, alone and in combination with other agents. These
forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially. These risks
and uncertainties include, among others, the factors described
under the Risk Factors section of our most recent Quarterly Report
on Form 10-Q or Annual Report on Form 10-K filed with the
Securities and Exchange Commission. Agenus cautions investors not
to place considerable reliance on the forward-looking statements
contained in this release. These statements speak only as of the
date of this press release, and Agenus undertakes no obligation to
update or revise the statements, other than to the extent required
by law. All forward-looking statements are expressly qualified in
their entirety by this cautionary statement.
ContactAgenus Inc.Divya
Vasudevan, PhD781-674-4571divya.vasudevan@agenusbio.com
Agenus Media RelationsKimberly HaKKH
Advisors917-291-5744kimberly.ha@kkhadvisors.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Mar 2023 to Mar 2024